KUALA LUMPUR, Malaysia, April 18, 2026 /PRNewswire/ — Ddrops® participated in the annual Sports Day hosted by Dripping Colours Montessori on April 18, 2026, reinforcing its commitment to supporting children’s healthy growth through active lifestyles and proper nutrition.

Serving children aged 2 to 6, Dripping Colours Montessori integrates Montessori principles that emphasize child-led learning, hands-on exploration, and holistic development. The Sports Day extended learning beyond the classroom, encouraging children to build physical strength, confidence, and resilience through movement and play.

Early childhood is a critical stage of growth, where proper nutrition plays a key role in supporting bone development, immune function, and overall well-being. Nutrients such as vitamins D and A are essential for helping children stay active and engaged in their daily learning experiences.

Aligned with this philosophy, Ddrops® offers a simple approach to daily supplementation. Its “one drop a day” format provides an easy and effective way for families to deliver essential nutrients, including vitamins A and D3, supporting calcium absorption, immune health, and eye health.

During the event, Ddrops® engaged with families through interactive activities and curated giveaways, helping parents better understand how to incorporate nutritional support into everyday routines.

Originating from Canada, Ddrops® is known for its clean formulations, free from added sugars, preservatives, artificial colors, and common allergens.

As the No. 1 pediatrician-recommended brand in Canada, Ddrops® is backed by a range of international certifications, including the Mom‘s Choice Award, GMP, NPN, NSF, SGS, USDA Organic, NPRA Certification, and HMA Halal, underscoring its commitment to quality and safety.

Its Vitamin A & D3 range was named “Best Liquid Vitamin A & D3 Supplement” at the 2025 Motherhood Choice Awards, while its Vitamin D3 range earned “Best Family Vitamin D Supplement” in 2024.

As Ddrops® continues to expand across Southeast Asia, it remains focused on providing safe, convenient, and high-quality nutritional solutions, supporting families in building strong foundations for children’s healthy development.

Source

GUANGZHOU, China, April 18, 2026 /PRNewswire/ — On April 15, the 139th Canton Fair opened in Guangzhou. As one of the world’s largest trade events, it gathers global buyers and leading manufacturers. TAILG participated under “Tech TAILG. Leading Globally,” presenting its full lineup of flagship products and demonstrating strength in electric mobility and global development.

On the opening day, TAILG appeared with one of the largest booth areas in the exhibition hall. Visitor traffic remained high throughout the day. Buyers from Europe, the Americas, and other regions—including new and long-term partners—visited the booth, highlighting TAILG’s global appeal.

Frontier Tech and Flagship Products

At the exhibition, TAILG showcased 22 models, including electric motorcycles, e-bikes, electric bicycles, and electric tricycles, meeting diverse mobility needs across global markets.

The F91 Ultra-L fast-charging model made a key appearance, featuring automotive-grade fast-charging technology and an integrated “vehicle + charging station” solution. It offers up to 150 km range and is equipped with a 50,000cd intelligent headlight and a TCS traction control system, delivering balanced performance in power, safety, and lighting.

The upgraded F55 model also attracted attention, featuring a refreshed design and optimized power system, further strengthening its competitiveness in global markets.

Global Presence and Trust

TAILG focuses on real-world mobility needs, optimizing product performance and supply capabilities worldwide. With years of overseas experience, its products have achieved stable performance in markets such as Vietnam, Iraq, and Morocco, supported by expanding distribution networks.

As a partner of the United Nations in electric mobility, TAILG participates in global low-carbon initiatives with international organizations to promote sustainable transport solutions.

Global Strategy

TAILG’s global leadership is built on its integrated R&D, manufacturing, and sales system. The company operates a national-level CNAS laboratory and a global low-carbon mobility research institute, holding over 2,000 patents and multiple international design awards.

It has established seven global R&D and production bases with an annual capacity of over 10 million units, ensuring stable global supply. Its retail network spans more than 27,000 stores across over 70 countries and regions.

Through continuous expansion, TAILG is strengthening its position in the electric mobility industry.

From the Canton Fair, TAILG accelerates global expansion through innovation. Looking ahead, the brand will deepen its global presence, enhance competitiveness, and expand its international market reach.

Source

HAIKOU, China, April 18, 2026 /PRNewswire/ — A report from the Hainan International Media Center:

In Haikou on April 16^th, during the 6th China International Consumer Products Expo, a book launch event was held to celebrate the publication of the China Development Report 2025 and the Global Development Report 2025, along with a Think Tank Dialogue themed around the high-quality development of the Hainan Free Trade Port (FTP). The books record China’s development process, offering holistic insights into global development, and giving the international community a more comprehensive and in-depth understanding of China’s and the world’s development trends.

The China Development Report 2025 records the achievements of China’s economic and social development in 2024 and also includes four important research findings from the Development Research Center of the State Council (DRC), while the Global Development Report 2025 responds to major concerns of the international community, lays out remaining certainties and favorable conditions, and explores an overall approach along with specific paths to promote global stability and sustainable development.

Since 2023, the global influence of both reports has significantly increased, reaching multiple developed countries and the Global South, as well as major international organizations, international think tanks, major multinational corporations, political figures, renowned economists, prestigious universities, and museums worldwide. They have also been collected by numerous domestic Party and government institutions, universities and research institutes, companies, industry associations, embassies, and consulates abroad, as well as other China-funded institutions. The reports have been featured at major conferences, renowned international and domestic book fairs, and important international forums, and have been established as think tank publications and public knowledge products with considerable international influence.

During the Think Tank Dialogue, experts exchanged views and offered targeted opinions and suggestions on how to better leverage the role of think tanks and contribute more wisdom and strength to the high-quality development of the Hainan FTP.

The DRC, a national high-end think tank, has published the two reports annually since 2023. The DRC’s Think Tank will also collaborate with the Southland Think Tank to conduct research into major issues concerning the high-quality development, institutional opening-up, and regional coordinated development of the Hainan FTP.

Source

The strategic collaboration brings together METT Singapore’s luxury event spaces, The MasterPlan LLP’s commercial and programme expertise, and UPGroup Asia’s AVL production, technical expertise, and integrated venue operations capabilities to deliver seamless, high-impact events at scale, strengthening the venue’s position in the MICE and premium events landscape.

SINGAPORE, April 18, 2026 /PRNewswire/ — METT Singapore, UPGroup Asia, and The MasterPlan today announced a strategic partnership agreement that brings together the lifestyle hotel’s luxury event spaces with UPGroup Asia’s advanced AVL production capabilities and The MasterPlan LLP’s expertise in high-value business events. The agreement was signed on 17 April 2026 at METT Singapore, 11 Canning Walk, Singapore, during METTUP 2026, a networking event for professionals from the MICE, hospitality and events industries.

Under the partnership, UPGroup Asia joins METT Singapore as its preferred AVL partner, delivering audio, visual, lighting, and livestream production solutions for events at the venue, while activating its Venue Management Programme to elevate the venue’s event operations.

“METT Singapore has the spaces and the character that corporate clients are increasingly looking for. Our role is to make sure the production side is seamless, so that the technical execution never gets in the way of the experience. Having The MasterPlan alongside us means that clients also have access to programme design and stakeholder management expertise from day one. That combination means clients have everything they need to deliver a high-quality event experience, in a venue that is already built for it.”

—  Adam Piperdy, Founder & Chief Experience Officer, UPGroup Asia

The MasterPlan, specialising in business-to-business events including conferences, seminars, product and media launches, C-level meetings, and curating customer experiences, takes on the role of preferred B2B event agency and programme partner, supporting event organisers in designing and executing programmes at METT Singapore.

“Our clients want venues that can deliver on the full promise of an event: the setting, the programme, and the production. METT Singapore gives us that setting, and working alongside UPGroup Asia means the production capability is already in place. For meeting planners and corporate clients looking for a venue that is both distinctive and operationally ready, METT Singapore delivers on both.”

— Jasmine Ho, Founder & Managing Partner, The MasterPlan LLP

The collaboration strengthens METT Singapore’s position as a destination of choice for corporate and MICE events. With UPGroup Asia’s audio, visual, and lighting solutions embedded across its event operations, METT Singapore is equipped to deliver seamless, high-impact experiences at every scale. Through The MasterPlan LLP’s enterprise client relationships and programme expertise, the venue becomes a natural destination for meeting planners, corporate clients, and premium brands seeking a distinctive address for their most important events.

“At METT Singapore, we have always believed in creating spaces that bring people together—thoughtfully designed to foster connection, engagement, and meaningful experiences. Partnering with UPGroup Asia and The MasterPlan LLP allows us to bring this vision to life, combining our environment with the production capabilities and event expertise that today’s corporate and MICE clients expect. We look forward to welcoming more organisations to experience all that METT Singapore has to offer.” 

— Marcel Li, General Manager, METT Singapore

METT Singapore is located within Fort Canning Park and is operated by Sunset Mett Sing Pte. Ltd. under the Sunset Hospitality Group. The hotel features 84 rooms and suites, a 950-square-metre Grand Ballroom and a 360-square-metre Junior Ballroom, alongside outdoor terrace spaces, offering a design-led environment for high-value corporate and luxury events.

ABOUT THE ORGANISATIONS

About UPGroup Asia

UPGroup Asia is an integrated event experience agency delivering event experiences in Singapore and Asia. Empowered by a team of creators, strategists, and experts who are deeply passionate about content, audience engagement, and event technology, UPGroup Asia delivers a complete suite of event solutions that allow event organisers to seamlessly execute award-winning event experiences. Producing hundreds of event experiences for thousands of audiences annually, UPGroup Asia is the trusted partner of both organisations and venue owners in the region.

About The MasterPlan LLP

At The MasterPlan, we specialise in the art of the B2B experience. We take the complexity of conferences, the wow moments at product launches, the prestige of CXO engagements, and the energy of brand activations, and distill them into a single, flawless execution. We cherish long-term partnerships and our clients’ brand and marketing objectives. Thus translating these understandings to great experiences and seamless execution onsite.

About METT Singapore

METT Singapore is a stylish 5-star city escape surrounded by nature that blends elegant colonial charm with contemporary soul. Nestled within the lush, historic grounds of Fort Canning Park, yet steps from Orchard Road, METT presents a destination where heritage meets high energy, social connections are celebrated, and next-generation wellness is embraced.

The iconic listed property, which celebrates its 100th anniversary this year offers 84 elegant and light-filled suites and rooms and bespoke event spaces designed to inspire unforgettable moments. At the heart of the experience is dining as a social ritual led by Michelin-starred Chef Daniele Sperindio, offering four distinctive concepts including L’Amo Bistrò del Mare, an ode to premium Italian coastal dining.

Hotel guests enjoy access to Madison House private members club, with two sparkling swimming pools, three padel and pickleball courts, a state-of-the-art fitness studio and wellness by The Longevity Suite.

MEDIA CONTACTS

UPGroup Asia
Josiah Eufemio  |  Marketing & Communications Lead  |  josiah_eufemio@upgroup.asia

The MasterPlan LLP
Laiyee Wong  |  Senior Project Manager  |  laiyee@themasterplan.com.sg

METT Singapore
Glenda Raphaela Dharma | Assistant Marketing Manager – Hotel | glenda.dharma@metthotelsandresorts.com

Source

SHANGHAI and HONG KONG, April 18, 2026 /PRNewswire/ — Antengene Corporation Limited  (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that it has released present results from three novel programs in poster presentations at the 2026 American Association for Cancer Research Annual Meeting (AACR 2026). The presentations will feature ATG-125 (B7-H3 x PD-L1 bispecific antibody-drug conjugate [ADC]), an IO + ADC dual-function molecule being developed for the treatment of solid tumors, as well as two investigational T cell engagers (TCEs) developed using the company’s proprietary AnTenGager^® TCE platform, including ATG-106 (CDH6 x CD3 TCE) for ovarian and kidney cancers, and ATG-112 (ALPPL2 x CD3 TCE) for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC.

Details of the Poster Presentation:
ATG-125 (B7-H3 x PD-L1 bispecific ADC)
Title: ATG-125, a novel B7H3 x PD-L1 bispecific antibody-drug conjugate, demonstrates potent antitumor efficacy by dual targeting of immune evasion and direct tumor killing
Abstract Number: 5599
Session Category: Immunology
Session Title: T Cell Engagers 2 / Antibody-Drug Conjugates 1
Date: April 21, 2026
Time: 02:00 PM – 05:00 PM (Pacific Time)
           05:00 AM, April 22, 2026 – 08:00 AM, April 22, 2026 (Beijing Time)
Location: Poster Section 8

• Introduction: B7-H3 and PD-L1 are immune checkpoint molecules broadly overexpressed across multiple solid tumors and are associated with immune evasion and poor prognosis. Although PD-1/PD-L1-directed therapies have demonstrated clinical benefit, treatment resistance remains a significant challenge. B7-H3 is also emerging as a promising ADC target due to its broad tumor expression and rapid internalization. ATG-125 is a novel B7-H3 x PD-L1 bispecific ADC designed to combine direct tumor killing with immune activation by co-targeting two complementary tumor-associated pathways in a single molecule.
• Results: ATG-125 bound to both B7-H3 and PD-L1 with high specificity and nanomolar affinity and demonstrated robust antigen-dependent internalization in dual-positive tumor cells, enabling efficient intracellular payload release. The molecule induced tumor cell apoptosis, while its parental naked antibody blocked PD-1/PD-L1 interaction and elicited IL-2 and IFN-γ production in mixed lymphocyte reaction assays. ATG-125 also enhanced T-cell activation, as reflected by an increased ratio of CD69+/CD3+ T cells in co-cultures of tumor cells and human PBMCs. In vivo, ATG-125 demonstrated sustained antitumor activity in HCC827 xenograft models, increased tumor infiltration of CD4+ and CD8+ T cells in PBMC-humanized models, and inhibited tumor growth in a dose-dependent manner in MC38-hB7H3 syngeneic models, accompanied by elevated intratumoral CD8+ T-cell infiltration.
• Conclusion: ATG-125 demonstrated synergistic IO+ADC antitumor activity through a differentiated mechanism combining enhanced internalization for payload delivery with the potential to restore anti-tumor immunity. Its compelling preclinical profile supports further development for patients with solid tumors.

ATG-106 (CDH6 x CD3 TCE)
Title: ATG-106, a novel “2+1” format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy
Abstract Number: 1621
Session Category: Immunology
Session Title: T Cell Engagers 1
Date: April 20, 2026
Time: 09:00 AM – 12:00 PM (Pacific Time)
           00:00 AM, April 21, 2026 – 03:00 AM, April 21, 2026 (Beijing Time)
Location: Poster Section 10

• Introduction: CDH6 plays an important role in embryonic kidney development but has negligible expression in adult kidney tissue. Its overexpression in ovarian and renal cancers, together with limited normal tissue expression, makes CDH6 an attractive therapeutic target. However, T cell engagers in solid tumors have often been limited by insufficient efficacy and the risk of cytokine release syndrome. To address these challenges, Antengene developed ATG-106, a novel “2+1”, sterically masked CDH6 x CD3 bispecific TCE designed to deliver potent antitumor activity with the potential for a reduced CRS risk profile.
• Results: ATG-106 exhibited reduced binding affinity to CD3+ cells before CDH6 crosslinking, while inducing approximately 100- to 400-fold more potent cytotoxicity against CDH6-positive tumor cells compared with a “1+1” CrossMab control TCE. The molecule demonstrated potent T cell-dependent cytotoxicity in ovarian and renal cancer models and showed low immunogenicity risk in vitro. In PBMC-humanized 786-O kidney cancer xenograft models, ATG-106 induced tumor shrinkage in all treated mice, with complete remissions observed in the 0.1 mg/kg and 0.3 mg/kg groups. ATG-106 also induced tumor shrinkage and complete remission in PBMC-humanized OVCAR-3 ovarian cancer models. Notably, pro-inflammatory cytokine levels remained very low in treated animals, suggesting low CRS risk. In non-human primate studies, the surrogate molecule ATG-106-RM was well tolerated at doses up to 10 mg/kg.
• Conclusion: ATG-106 demonstrated limited T cell binding in the absence of target cells, potent cytotoxicity against tumor cells, and encouraging in vivo efficacy in ovarian and kidney cancer models. Favorable safety findings with the surrogate molecule in non-human primates further support continued clinical development of ATG-106 as a CDH6-targeted TCE candidate.

ATG-112 (ALPPL2 x CD3 TCE)
Title: ATG-112, a novel ALPP/G x CD3 bispecific T cell engager, for the treatment of ALPP/G⁺ solid tumors
Abstract Number: 1620
Session Category: Immunology
Session Title: T Cell Engagers 1
Date: April 20, 2026
Time: 09:00 AM – 12:00 PM (Pacific Time)
           00:00 AM, April 21, 2026 – 03:00 AM, April 21, 2026 (Beijing Time)
Location: Poster Section 10

• Introduction: Placental alkaline phosphatase and related placental-like/germ-cell isoforms, including ALPPL2 and ALPG, are aberrantly expressed in a range of solid tumors while being largely absent from normal adult tissues except the placenta, making them highly promising tumor-selective immunotherapy targets. Antengene developed ATG-112, an ALPP/G x CD3 bispecific TCE based on the AnTenGager^® platform in a “2+1” format, featuring bivalent antigen binding to improve low-antigen tumor recognition and a sterically masked CD3 binding arm designed to restrict T-cell activation to the tumor microenvironment.
• Results: Tissue microarray IHC analysis showed that ALPP/G expression was restricted to placental tissue among normal organs and was not detected in other normal tissues, while frequent expression was observed in endometrial and ovarian cancers, with lower prevalence in bladder, gastric and pancreatic cancers. ATG-112 demonstrated high binding affinity to both ALPP/G-positive tumor cells and recombinant proteins, with EC50 and KD values in the sub-nanomolar range. It induced robust T cell-dependent cytotoxicity against target-positive cells with picomolar EC50 values, while in vitro cytokine-release assays showed minimal cytokine secretion from human PBMCs. In vitro studies also demonstrated that the spatial masking effect of ATG-112 is reversible. Immunogenicity assessment showed low immunogenic potential, and in vivo ATG-112 delivered potent tumor suppression across multiple dose levels in humanized mouse models, with low cytokine release and controllable CRS risk at efficacious doses. The program also demonstrated strong developability characteristics.
• Conclusion: ATG-112 demonstrated a compelling preclinical profile, with potent in vitro and in vivo antitumor activity and minimal cytokine release. These findings support the continued advancement of ATG-112 toward clinical development for solid tumors.

About Antengene
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), and ATG-125 (B7-H3 × PD-L1 bispecific ADC).

Antengene has also developed AnTenGager^®, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO^® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com  

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com 

Source

Lunit’s AACR 2026 presentations showed how AI-driven biomarkers can improve the efficiency of clinical workflows, uncover spatial features of the tumor microenvironment not captured by conventional methods, and enable integrated analysis to better support treatment decision-making.

SEOUL, South Korea, April 18, 2026 /PRNewswire/ — Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, presented six studies at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from April 17 to 22 in San Diego, California.

The presentations highlighted Lunit’s continued advancements in AI-driven biomarker development, tumor microenvironment (TME) analysis, and real-world clinical applicability. Several studies were conducted in collaboration with global partners, including Agilent Technologies.

In a study conducted with Agilent Technologies and Ajou University Medical Center, researchers used Lunit SCOPE IO and uIHC to analyze over 25,000 non-small cell lung cancer (NSCLC) samples. The results showed that tumors with high c-MET expression exhibited a significant reduction in immune cell density within 30 μm of tumor cells (p<0.001), revealing a spatial immune exclusion pattern not captured by conventional analysis. These findings suggest a potential link between c-MET overexpression and immune evasion, supporting combination strategies involving MET-targeted therapy and immunotherapy.

Researchers also present findings from an exploratory analysis of the phase II MOUNTAINEER trial, demonstrating that AI- quantified HER2 expression is strongly associated with treatment response in patients with HER2-positive metastatic colorectal cancer treated with tucatinib plus trastuzumab. The overall objective response rate (ORR) was 43.4%, increasing to as high as 80% in patients with higher HER2 expression, indicating a clearer dose-dependent relationship. Tumor-Infiltrating Lymphocyte (TIL) density independently predicted progression-free survival. Notably, patients with low stromal TIL levels showed no response (ORR 0%) and a significantly higher risk of disease progression.

These findings highlight the increasing complexity of biomarker assessment, where both tumor characteristics and immune context need to be considered, underscoring the potential role of AI in supporting treatment decision-making.

In addition to these representative studies, Lunit presented additional research abstracts at AACR 2026, further demonstrating the breadth of its AI-powered oncology research. These include studies on

• AI-based analysis of tumor-infiltrating lymphocyte in NSCLC in collaboration with Dr. David Rimm’s lab at Yale University School of Medicine
• AI-based target discovery for bi-specific antibodies
• Biomarker research in CD47-targeted therapies

“Our AACR presentations reflect how AI is increasingly translating into real-world clinical impact” said Brandon Suh, CEO of Lunit. “Across these studies, we demonstrate how AI-driven biomarkers can enhance precision, deepen our understanding of tumor biology and increasingly support treatment decision-making in clinical practice.”

Visit Lunit at Booth #2248 during AACR 2026 to learn more about its latest research and AI-powered solutions in cancer diagnostics and therapeutics.

Lunit’s featured presentations at AACR 2026 include:

[Poster #0011/11] Artificial intelligence-based spatial analysis of the local tumor microenvironment in relation to c-MET expression in non-small cell lung cancer
April 19, 2:00 PM – 5:00 PM, Section 1

[Poster #7735/26] HER2 expression and tumor-infiltrating lymphocytes predict response to tucatinib plus trastuzumab in HER2-positive metastatic colorectal cancer (MOUNTAINEER): Exploratory analysis of a multicenter, Phase II trial
April 22, 9:00 AM – 12:00 PM, Section 41

[Poster #4415/23] AI-powered analysis of millions of IHC images identifies 19 spatially highly co-expressed protein pairs to enable bispecific antibody development
April 21, 9:00 AM – 12:00 PM, Section 11

[Poster #0080/11] Quantitative assessment of tumor-infiltrating lymphocytes using AI in non-small cell lung cancer and association with immunotherapy response
April 19, 2:00 PM – 5:00 PM, Section 4

[Poster #4355/26] Cryo EM-based structural characterization of IMC-002, a next-generation anti-CD47 antibody with a unique binding site and biomarker candidates, supporting evidence of enhanced safety and efficacy
April 21, 9:00 AM – 12:00 PM, Section 9

About Lunit

Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.

Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.

Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

About Lunit SCOPE

Lunit SCOPE is a suite of AI-powered software that analyzes tissue slide images for digital pathology and AI biomarker development, aiming to optimize workflow and facilitate more accurate and predictive clinical data for clinicians and researchers. Lunit SCOPE platform offers multiple AI-powered tissue analysis products and assays that can streamline digital pathology workflow and diagnostics and enhance the drug development process. Lunit SCOPE IO analyzes the tumor microenvironment (TME) based on H&E analysis and provides AI-based predictive clinical outcome information. In addition, AI-driven Immunohistochemistry (IHC) slide analysis services are offered through products such as Lunit SCOPE PD-L1, Lunit SCOPE HER2, Lunit SCOPE ER/PR, and others.

Source